Payment overview · 2025
General Payments
$12,044.10
122 reported records · 28 companies
Healthcare provider profile · identity verified
Larry Van Thomas Crisco, MD
Allopathic & Osteopathic Physicians|Internal Medicine|Interventional Cardiology · JACKSONVILLE, FL · NPI 1952395782
Verified facts
What the public records show
CMS Open Payments records show Larry Van Thomas Crisco, MD received $12,044.10 in general payments during 2025 across 122 reported records.
Medtronic, Inc. accounted for 76.5% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 41 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Entresto, Farxiga, Jardiance.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 101 claims for Farxiga by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 123636 records involving 49438 distinct recipient NPIs. Public Medicare Part D data also shows 53 claims for Jardiance by this doctor in 2024.
Celgene Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 25 records involving 24 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Eliquis by this doctor in 2024.
Novartis Pharmaceuticals Corporation reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ENTRESTO as an associated drug or biological on 9346 records involving 6254 distinct recipient NPIs. Public Medicare Part D data also shows 151 claims for Entresto by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Medtronic, Inc. |
Medtronic, Inc. exact · evidence 2025-07-22 |
$9,214.26 | 76.5% | 57 | 2025 |
| ABIOMED | Unresolved — no canonical attribution shown | $640.43 | 5.3% | 7 | 2025 |
| Endologix LLC | Unresolved — no canonical attribution shown | $490.22 | 4.1% | 5 | 2025 |
| Boston Scientific Corporation | Unresolved — no canonical attribution shown | $360.33 | 3.0% | 6 | 2025 |
| Shockwave Medical, Inc | Unresolved — no canonical attribution shown | $257.13 | 2.1% | 2 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $156.33 | 1.3% | 7 | 2025 |
| AngioDynamics, Inc. | Unresolved — no canonical attribution shown | $91.77 | 0.8% | 4 | 2025 |
| Alnylam Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $82.08 | 0.7% | 4 | 2025 |
| Stryker Corporation | Unresolved — no canonical attribution shown | $76.32 | 0.6% | 2 | 2025 |
| Kestra Medical Technology Services, Inc. | Unresolved — no canonical attribution shown | $75.17 | 0.6% | 3 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $61.20 | 0.5% | 3 | 2025 |
| Edwards Lifesciences Corporation | Unresolved — no canonical attribution shown | $58.34 | 0.5% | 2 | 2025 |
| Merck Sharp & Dohme LLC | Unresolved — no canonical attribution shown | $54.61 | 0.5% | 3 | 2025 |
| Vital Connect, Inc | Unresolved — no canonical attribution shown | $42.35 | 0.3% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $41.50 | 0.3% | 2 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $38.24 | 0.3% | 1 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $36.76 | 0.3% | 2 | 2025 |
| Neuros Medical, Inc. | Unresolved — no canonical attribution shown | $36.67 | 0.3% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $29.46 | 0.2% | 1 | 2025 |
| CORDIS US CORP. | Unresolved — no canonical attribution shown | $27.30 | 0.2% | 1 | 2025 |
| Acist Medical Systems, Inc. | Unresolved — no canonical attribution shown | $24.85 | 0.2% | 1 | 2025 |
| Teleflex LLC | Unresolved — no canonical attribution shown | $24.64 | 0.2% | 1 | 2025 |
| ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | Unresolved — no canonical attribution shown | $24.05 | 0.2% | 1 | 2025 |
| United Therapeutics Corporation | Unresolved — no canonical attribution shown | $23.90 | 0.2% | 1 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $20.63 | 0.2% | 1 | 2025 |
| Celgene Corporation | Unresolved — no canonical attribution shown | $19.36 | 0.2% | 1 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $19.00 | 0.2% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $17.20 | 0.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Travel and Lodging | $7,085.34 | 13 |
| Food and Beverage | $4,958.76 | 109 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| ONYX FRONTIER Normalized: onyx frontier |
Device | Medtronic, Inc. | $975.63 | 12 | 2025 |
Source payment records
|
|||||
| TURBOHAWK Normalized: turbohawk |
Device | Medtronic, Inc. | $288.00 | 1 | 2025 |
Source payment records
|
|||||
| General - Vascular Intervention Normalized: general vascular intervention |
Device | Boston Scientific Corporation | $285.49 | 3 | 2025 |
Source payment records
|
|||||
| Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter Normalized: shockwave ivl system with the shockwave c2 coronary ivl catheter |
Device | Shockwave Medical, Inc | $257.13 | 2 | 2025 |
Source payment records
|
|||||
| SYMPLICITY G3 Normalized: symplicity g3 |
Device | Medtronic, Inc. | $228.23 | 3 | 2025 |
Source payment records
|
|||||
| ENDOCROSS Device Normalized: endocross device |
Device | Endologix LLC | $171.31 | 1 | 2025 |
Source payment records
|
|||||
| Torus Stent Graft System Normalized: torus stent graft system |
Device | Endologix LLC | $171.31 | 1 | 2025 |
Source payment records
|
|||||
| ENDURANT IIS Normalized: endurant iis |
Device | Medtronic, Inc. | $158.92 | 1 | 2025 |
Source payment records
|
|||||
| TELESCOPE Normalized: telescope |
Device | Medtronic, Inc. | $145.98 | 13 | 2025 |
Source payment records
|
|||||
| DRAGONFLY OPSTAR Normalized: dragonfly opstar |
Device | Abbott Laboratories | $113.36 | 5 | 2025 |
Source payment records
|
|||||
| Alto Abdominal Stent Graft System Normalized: alto abdominal stent graft system |
Device | Endologix LLC | $107.40 | 1 | 2025 |
Source payment records
|
|||||
| AURYON LASER SYSTEM 100-120 VAC Normalized: auryon laser system 100 120 vac |
Device | AngioDynamics, Inc. | $91.77 | 4 | 2025 |
Source payment records
|
|||||
| AMVUTTRA Normalized: amvuttra |
Drug | Alnylam Pharmaceuticals Inc. | $82.08 | 4 | 2025 |
Source payment records
|
|||||
| Assure WCD Normalized: assure wcd |
Device | Kestra Medical Technology Services, Inc. | $75.17 | 3 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $61.20 | 3 | 2025 |
Source payment records
|
|||||
| SAPIEN 3 Ultra RESILIA Normalized: sapien 3 ultra resilia |
Device | Edwards Lifesciences Corporation | $58.34 | 2 | 2025 |
Source payment records
|
|||||
| VERQUVO Normalized: verquvo |
Drug | Merck Sharp & Dohme LLC | $54.61 | 3 | 2025 |
Source payment records
|
|||||
| LIMFLOW SYSTEM Normalized: limflow system |
Device | Stryker Corporation | $54.26 | 1 | 2025 |
Source payment records
|
|||||
| COMPLETE SE VASCULAR Normalized: complete se vascular |
Device | Medtronic, Inc. | $47.32 | 5 | 2025 |
Source payment records
|
|||||
| VITALPATCH RTM Normalized: vitalpatch rtm |
Device | Vital Connect, Inc | $42.35 | 1 | 2025 |
Source payment records
|
|||||
| JARDIANCE Normalized: jardiance |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $41.50 | 2 | 2025 |
Source payment records
|
|||||
| Eagle Eye Normalized: eagle eye |
Device | Philips North America LLC | $38.24 | 1 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $36.76 | 2 | 2025 |
Source payment records
|
|||||
| Altius Normalized: altius |
Device | Neuros Medical, Inc. | $36.67 | 1 | 2025 |
Source payment records
|
|||||
| WATCHMAN FLX Normalized: watchman flx |
Device | Boston Scientific Corporation | $31.73 | 1 | 2025 |
Source payment records
|
|||||
| EVKEEZA Normalized: evkeeza |
Biological | Regeneron Healthcare Solutions, Inc. | $29.46 | 1 | 2025 |
Source payment records
|
|||||
| DIAMONDBACK CORONARY Normalized: diamondback coronary |
Device | Abbott Laboratories | $27.79 | 1 | 2025 |
Source payment records
|
|||||
| MYNX CONTROL Normalized: mynx control |
Device | CORDIS US CORP. | $27.30 | 1 | 2025 |
Source payment records
|
|||||
| CVI Systems Normalized: cvi systems |
Device | Acist Medical Systems, Inc. | $24.85 | 1 | 2025 |
Source payment records
|
|||||
| ORSIRO MISSION Normalized: orsiro mission |
Device | Teleflex LLC | $24.64 | 1 | 2025 |
Source payment records
|
|||||
| LifeVest Normalized: lifevest |
Device | ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) | $24.05 | 1 | 2025 |
Source payment records
|
|||||
| Tyvaso Normalized: tyvaso |
Drug | United Therapeutics Corporation | $23.90 | 1 | 2025 |
Source payment records
|
|||||
| Rhythmia Mapping System Normalized: rhythmia mapping system |
Device | Boston Scientific Corporation | $23.07 | 1 | 2025 |
Source payment records
|
|||||
| ARTIX MT Normalized: artix mt |
Device | Stryker Corporation | $22.06 | 1 | 2025 |
Source payment records
|
|||||
| ENTRESTO Normalized: entresto |
Drug | Novartis Pharmaceuticals Corporation | $21.63 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $20.63 | 1 | 2025 |
Source payment records
|
|||||
| ROTAPRO Normalized: rotapro |
Device | Boston Scientific Corporation | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $19.00 | 1 | 2025 |
Source payment records
|
|||||
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $17.20 | 1 | 2025 |
Source payment records
|
|||||
| XACT Normalized: xact |
Device | Abbott Laboratories | $15.18 | 1 | 2025 |
Source payment records
|
|||||
| MICRA Normalized: micra |
Device | Medtronic, Inc. | $5.08 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ENTRESTO entresto |
2025 | Entresto | 2024 | 151 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 101 | exact normalized | Medicare Part D |
| JARDIANCE jardiance |
2025 | Jardiance | 2024 | 53 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
101 | 35 |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 123636 supporting records · 49438 recipient NPIs · example record 1221811583 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
53 | 24 |
| Celgene Corporation Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 25 supporting records · 24 recipient NPIs · example record 1184385048 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
215 | 55 |
| Novartis Pharmaceuticals Corporation Exact reporting entity; no affiliate inference |
2025 | ENTRESTO open payments reported associated product |
CMS Open Payments — General Payments 9346 supporting records · 6254 recipient NPIs · example record 1200004797 |
Entresto · 2024 Exact normalized brand match · 1 Part D row |
151 | 35 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Clopidogrel | Clopidogrel Bisulfate | 510 | 191 |
| Spironolactone | Spironolactone | 410 | 132 |
| Atorvastatin Calcium | Atorvastatin Calcium | 301 | 97 |
| Amlodipine Besylate | Amlodipine Besylate | 270 | 96 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 258 | 96 |
| Metoprolol Succinate | Metoprolol Succinate | 249 | 96 |
| Carvedilol | Carvedilol | 245 | 93 |
| Eliquis | Apixaban | 215 | 55 |
| Pravastatin Sodium | Pravastatin Sodium | 211 | 83 |
| Losartan Potassium | Losartan Potassium | 201 | 69 |
| Lisinopril | Lisinopril | 169 | 64 |
| Entresto | Sacubitril/Valsartan | 151 | 35 |
| Cilostazol | Cilostazol | 142 | 47 |
| Xarelto | Rivaroxaban | 135 | 43 |
| Candesartan Cilexetil | Candesartan Cilexetil | 116 | 41 |
| Metoprolol Tartrate | Metoprolol Tartrate | 109 | 38 |
| Farxiga | Dapagliflozin Propanediol | 101 | 35 |
| Hydrochlorothiazide | Hydrochlorothiazide | 91 | 32 |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 84 | 36 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 71 | 24 |
| Ezetimibe | Ezetimibe | 68 | 25 |
| Furosemide | Furosemide | 62 | 29 |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 58 | 22 |
| Ranolazine Er | Ranolazine | 58 | 14 |
| Valsartan | Valsartan | 58 | 26 |
| Nitroglycerin | Nitroglycerin | 56 | 34 |
| Jardiance | Empagliflozin | 53 | 24 |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 48 | 14 |
| Potassium Chloride | Potassium Chloride | 43 | 18 |
| Bisoprolol-Hydrochlorothiazide | Bisoprolol/Hydrochlorothiazide | 41 | 19 |
| Repatha Sureclick | Evolocumab | 41 | suppressed |
| Irbesartan | Irbesartan | 37 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 33 | suppressed |
| Amiodarone Hcl | Amiodarone Hcl | 25 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 23 | suppressed |
| Simvastatin | Simvastatin | 23 | suppressed |
| Sotalol | Sotalol Hcl | 23 | suppressed |
| Pantoprazole Sodium | Pantoprazole Sodium | 22 | 11 |
| Brilinta | Ticagrelor | 20 | suppressed |
| Prasugrel Hcl | Prasugrel Hcl | 20 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 19 | suppressed |
| Chlorthalidone | Chlorthalidone | 17 | suppressed |
| Ramipril | Ramipril | 15 | suppressed |
| Nifedipine Er | Nifedipine | 13 | suppressed |
| Livalo | Pitavastatin Calcium | 12 | suppressed |
| Allopurinol | Allopurinol | 11 | suppressed |
| Dilt-Xr | Diltiazem Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $12,044.10 · 122 records | Medtronic, Inc. | AMVUTTRA, ARTIX MT, AURYON LASER SYSTEM 100-120 VAC, Altius, Alto Abdominal Stent Graft System, Assure WCD, COMPLETE SE VASCULAR, CVI Systems, DIAMONDBACK CORONARY, DRAGONFLY OPSTAR, ENDOCROSS Device, ENDURANT IIS, ENTRESTO, EVKEEZA, Eagle Eye, FARXIGA, General - Vascular Intervention, JARDIANCE, Kerendia, LEQVIO, LIMFLOW SYSTEM, LifeVest, MICRA, MYNX CONTROL, ONYX FRONTIER, ORSIRO MISSION, REPATHA, ROTAPRO, Rhythmia Mapping System, SAPIEN 3 Ultra RESILIA, SYMPLICITY G3, Shockwave IVL System with the Shockwave C2 Coronary IVL Catheter, TELESCOPE, TURBOHAWK, Torus Stent Graft System, Tyvaso, VERQUVO, VITALPATCH RTM, WATCHMAN FLX, Wegovy, XACT | 5 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Entresto play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error